Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2018

View Archived Issues

Cleaning up synuclein

Crystal structure of Pseudomonas exotoxins and human 14-3-3 protein identifies a new target

ASM opens BBB in aging

Preclinical results presented for novel 6-amino-6-deoxy paramylon for the treatment of obesity

Novel anti-inflammatory CXCL12 neutraligand with improved characteristics discovered

Nilvadipine does not demonstrate efficacy in patients with mild to moderate Alzheimer's disease

Novel Janssen hepatitis B virus capsid assembly modulators possess potent antiviral activity

Hemispherx and Roswell Park enter clinical trial agreement to study Ampligen

U.S. DoD funding phase II combination study of TPIV-110 in breast cancer

Helix BioPharma, Moffitt Cancer Center expand collaboration

The nitty gritty: Drilling down into sepsis shows routes to treatment

Urinary exosomal CCL-21 mRNA as marker of histological injury and renal function deterioration in DN

PF-06939926 induces a greater amelioration of DMD pathology when administered at a younger age

GS-6207 shows long-acting nonclinical pharmacokinetic profile

R-DMDdel52, a new rat model of Duchenne muscular dystrophy, developed

Hypermethylation of miR-145-5p drives laryngeal squamous cell carcinoma invasion and metastasis

Chinese researchers patent adenosine A2A receptor antagonists

Gedeon Richter presents GABA-B receptor PAMs

New phase II/III trial in Brazil studies meningococcus C vaccine MenCC-Bio

Genentech and Roche identify MAP4K1 inhibitors

Cognition Therapeutics begins phase II trial of CT-1812 in mild to moderate Alzheimer's disease

Cardio Therapeutics patent describes PCSK9 inhibitors

Galera initiates phase III study of GC-4419 to reduce radiation-induced oral mucositis

Athenex discloses CRAC modulators as IL-2 production inhibitors

Perjeta approved in Japan for neoadjuvant and adjuvant use in HER2-positive early breast cancer

ASSESS trial demonstrates superior efficacy of Gilenya over Copaxone in relapsing-remitting MS

Ritter presents additional phase IIb data on RP-G28 for treatment of lactose intolerance

Stelara induces clinical remission and response in moderate to severe ulcerative colitis

Pharmaxis reports phase I data for first LOXL2 inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...